These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19520676)

  • 1. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
    Pineo GF; Hull RD
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
    Wilbur K; Lynd LD; Sadatsafavi M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular-weight heparin in prevention and treatment.
    Merli GJ
    J Thromb Thrombolysis; 2004 Oct; 18(2):117-25. PubMed ID: 15789178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
    McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
    Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolic risk and its prevention in hospitalized medical patients.
    Haas SK
    Semin Thromb Hemost; 2002 Dec; 28(6):577-84. PubMed ID: 12536351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
    Bradley CT; Brasel KJ; Miller JJ; Pappas SG
    Ann Surg Oncol; 2010 Jan; 17(1):31-9. PubMed ID: 19707830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building effective prophylaxis of deep vein thrombosis in the outpatient setting.
    Agnelli G; Taliani MR; Verso M
    Blood Coagul Fibrinolysis; 1999 Aug; 10 Suppl 2():S29-35. PubMed ID: 10493228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rationale for long-term prophylaxis of venous thromboembolism.
    Agnelli G; Mancini GB; Biagini D
    Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
    Shorr AF; Jackson WL; Weiss BM; Moores LK
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
    Cohen AT; Nandini B; Wills JO; Ota S
    Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.